# PK Study of IV Formulation of GW856553

> **NCT01039961** · PHASE1 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 16 (actual)

## Conditions studied

- Cardiovascular Disease

## Interventions

- **DRUG:** losmapimod 1 mg
- **DRUG:** losmapimod
- **DRUG:** losmapimod 15 mg

## Key facts

- **NCT ID:** NCT01039961
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-02-02
- **Primary completion:** 2010-04-15
- **Final completion:** 2010-04-15
- **Target enrollment:** 16 (ACTUAL)
- **Last updated:** 2017-06-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01039961

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01039961, "PK Study of IV Formulation of GW856553". Retrieved via AI Analytics 2026-05-29 from https://api.ai-analytics.org/clinical/NCT01039961. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*